Lone Wolfe: Drug Industry Critic Ends Tenure As Advisory Committee Member With Rare Decisive Vote
This article was originally published in RPM Report
Executive Summary
Sidney Wolfe’s stint as permanent member of the Drug Safety and Risk Management Advisory Committee ended May 31; his final meeting was the May 23 review of Xarelto for ACS. That gave him a second chance to vote against the product. A look back at Wolfe’s tenure shows he was a sure “no” vote when he sat on a panel—but that his service can hardly be construed as having damaged the industry.
You may also be interested in...
“Do Not Compound” List One Step Closer, After FDA Names Advisors
FDA’s pharmacy compounding efforts in 2015 should include additional guidance and work by an advisory committee to build a “do-not-compound” list.
Mystery Adcomm Revealed
In 2011, FDA held an unusual closed-door advisory committee meeting on a Phase III product – with Public Citizen’s Sid Wolfe as one panelist. The identity of the drug was finally revealed ahead of a second, open committee meeting.
TMI from TIMI: Xarelto and the Trouble with Very Large Trials
With bigger clinical trials come potentially bigger problems. That, at least, is what sponsors of 15,000-plus trials in cardiovascular medicine are finding out. J&J/Bayer’s experience in late May with Xarelto for acute coronary syndrome is a case in point—and it also provides timely context for the surprising setback for another CV project, Pfizer/BMS' Eliquis.